SUNY Downstate Medical Center, Department of Neurology, Brooklyn, NY, USA.
Debina Diagnostic Inc., Newtown Square, PA, USA,
Int J Nanomedicine. 2019 Feb 14;14:1163-1175. doi: 10.2147/IJN.S189048. eCollection 2019.
Thromboembolic events are a major cause of heart attacks and strokes. However, diagnosis of the location of high risk vascular clots is hampered by lack of proper technologies for their detection. We recently reported on bio-engineered fluorescent diamond-(NV)-Z~800nm (FNDP-(NV)) conjugated with bitistatin (Bit) and proven its ability to identify iatrogenic blood clots in the rat carotid artery in vivo by Near Infra-Red (NIR) monitored by In Vivo Imaging System (IVIS).
The objective of the present research was to assess the in vivo biocompatibility of FNDP-(NV)-Z~800nm infused intravenously to rats. Multiple biological variables were assessed along this 12 week study commissioned in anticipation of regulatory requirements for a long-term safety assessment.
Rats were infused under anesthesia with aforementioned dose of the FNDP-(NV), while equal number of animals served as control (vehicle treated). Over the 12 week observation period rats were tested for thriving, motor, sensory and cognitive functions. At the termination of study, blood samples were obtained under anesthesia for comprehensive hematology and biochemical assays. Furthermore, 6 whole organs (liver, spleen, brain, heart, lung and kidney) were collected and examined ex vivo for FNDP-NV) via NIR monitored by IVIS and histochemical inspection.
All animals survived, thrived (no change in body and organ growth). Neuro-behavioral functions remain intact. Hematology and biochemistry (including liver and kidney functions) were normal. Preferential FNDP-(NV) distribution identified the liver as the main long-term repository. Certified pathology reports indicated no outstanding of finding in all organs.
The present study suggests outstanding biocompatibility of FNDP-(NV)-Z~800nm after long-term exposure in the rat.
血栓栓塞事件是心脏病发作和中风的主要原因。然而,由于缺乏适当的技术来检测高风险血管血栓,因此对其位置的诊断受到了阻碍。我们最近报道了生物工程荧光金刚石-(NV)-Z~800nm(FNDP-(NV))与比替司他汀(Bit)偶联,并通过体内成像系统(IVIS)监测近红外(NIR)证明了其在体内识别大鼠颈动脉医源性血栓的能力。
本研究的目的是评估静脉内注射 FNDP-(NV)-Z~800nm 的体内生物相容性。在进行这项为期 12 周的研究时,考虑到长期安全性评估的监管要求,评估了多个生物学变量。
在麻醉下,用上述剂量的 FNDP-(NV)给大鼠输注,同时用等量的动物作为对照(用载体处理)。在 12 周的观察期间,对大鼠进行了生存、运动、感觉和认知功能的测试。在研究结束时,在麻醉下获取血液样本,进行全面的血液学和生化分析。此外,收集 6 个完整器官(肝、脾、脑、心、肺和肾),通过 IVIS 监测的 NIR 进行 FNDP-NV)体外检测,并进行组织化学检查。
所有动物均存活,生长良好(身体和器官生长无变化)。神经行为功能保持完整。血液学和生物化学(包括肝功能和肾功能)正常。优先的 FNDP-(NV)分布将肝脏确定为主要的长期储存库。经认证的病理报告表明,所有器官均无异常发现。
本研究表明,FNDP-(NV)-Z~800nm 在大鼠体内长期暴露后具有出色的生物相容性。